KeyBanc reiterates Omnicell stock rating on Titan XT launch

KeyBanc reiterates Omnicell stock rating on Titan XT launch

Gold slides as U.S.-Iran conflict lifts oil, hawkish Fed bets grow Investing.com - KeyBanc reiterated an Overweight rating and $70.00 price target on Omnicell (NASDAQ:OMCL) shares following the company’s product launch. The stock has delivered a 56.57% return over the past year, though it currently trades about 18% below its 52-week high of $55. According to InvestingPro analysis, the company appears undervalued at current levels and boasts a perfect Piotroski Score of 9, indicating strong financial health.

The investment firm maintained its positive stance on the healthcare technology company as it introduces its Titan XT Cabinets to the market. KeyBanc analyst Scott Schoenhaus stated: "Launch of Titan XT Cabinets Unlocks Major Strategic Catalysts. OMCL’s Titan XT is an enterprise platform able to connect to a multitude of devices, allowing it to collect even more data."

The analyst added: "Titan XT is meant for a growing health system, allows for central capability/dynamic restocking capabilities and simplifies pharmacy tasks via intelligent alerts, and deploys more AI to help with proactive decisions. "Investor confidence in Omnicell remains strong, with 7 analysts recently revising their earnings estimates upward. For deeper insights, including 14 additional InvestingPro Tips and comprehensive financial analysis, investors can access the full Pro Research Report available for OMCL.

The Titan XT platform represents an enterprise solution designed to integrate with multiple devices and enhance data collection capabilities for healthcare systems. In other recent news, Omnicell, Inc. reported first-quarter fiscal 2026 adjusted EBITDA of $44.7 million, surpassing expectations by 42% and exceeding the high end of guidance by $11.7 million. This strong performance led Piper Sandler to raise its price target for Omnicell shares to $57, up from $49, while maintaining an Overweight rating.

However, Piper Sandler later lowered the price target slightly to $55 due to more moderate calendar year 2027 EBITDA estimates, still keeping the Overweight rating. KeyBanc also adjusted its outlook, raising Omnicell’s price target to $70 from $60, highlighting the growth potential driven by the demand for the newly launched Titan XT cabinets. In leadership developments, Omnicell announced the appointment of Nnamdi Njoku as President, who will continue in his role as Chief Operating Officer.

Additionally, Dan Mandoli has been named Senior Vice President and General Manager of Specialty Pharmacy Services, bringing over 30 years of experience to oversee the Specialty Pharmacy and 340B businesses. These leadership changes align with the company’s strategic focus on evolving its solution portfolio and expanding its specialty pharmacy services.